Weaving along Hawaii's Na Pali Coast is the famous, breathtaking Kalalau trail. This trail is not only notable for its strenuous path and terrain that is difficult to traverse but also known for its unsurpassed beauty. Kalalau was early inspiration for us, today representing out innovative spirit and deep commitment to advancing the treatment of eye diseases.
Kala is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY® mucus-penetrating particle (MPP) Drug Delivery Technology to two ocular therapies, EYSUVIS™ (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of signs and symptoms of dry eye disease and INVELTYS® (loteprednol etabonate ophthalmic suspension) 1% for the treatment of post-operative inflammation and pain following ocular surgery. The Company also has a pipeline of pre-clinical development programs targeted to address unmet medical needs, including both front and back of the eye diseases.
Location: United States, Massachusetts, Arlington
Employees: 51-200
Total raised: $218.2M
Founded date: 2009
Investors 8
Funding Rounds 5
| Date | Series | Amount | Investors | Deal News |
| 02.10.2018 | - | $110M | - | biospace.c... |
| 13.04.2016 | Series C | $68M | - | vcnewsdail... |
| 23.04.2014 | Series B | $22.5M | - | vcnewsdail... |
| 28.02.2013 | Series A | $11.5M | - | vcnewsdail... |
| 14.03.2012 | - | $6.2M | - | finsmes.co... |
Mentions in press and media 24
| Date | Title | Description | Source |
| 28.11.2022 | Kala Pharmaceuticals Announces Up to $31 Million Private Pla... | - | globenewsw... |
| 15.11.2021 | Kala Pharmaceuticals Announces Time Change for Third Quarter... | WATERTOWN, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a comm... | marketscre... |
| 15.11.2021 | Kala Pharmaceuticals Acquires Combangio, Expanding its Pipel... | -- KPI-012 is a novel secretome with a multifactorial mechanism of action for development in PCED an... | marketscre... |
| 21.07.2017 | Kala Pharmaceuticals, compañía participada por Ysios, anunci... | 21/07/2017 Nota de prensa KALA PHARMACEUTICALS, COMPAÑÍA PARTICIPADA POR YSIOS CAPITAL, ANUNCIA SU... | webcapital... |
| 07.06.2016 | Longitude Capital raises $525M for third fund spanning early... | The investment firm expects to invest an average of $15 million to 25 million per investment in appr... | medcitynew... |
| 14.04.2016 | Kala Pharmaceuticals cierra una ronda de $68 millones, acude... | 14/04/2016 KALA PHARMACEUTICALS CIERRA UNA RONDA DE $68 MILLONES, ACUDE YSIOS CAPITAL. La gestora ... | webcapital... |
| 13.04.2016 | Kala Pharmaceuticals Closes $68M in Series C | WALTHAM, MA, Developer of ophthalmic products based on muscle-penetrating particle technology, has... | vcnewsdail... |
| 13.04.2016 | Kala Pharmaceuticals Closes $68M Series C Financing | Kala Pharmaceuticals, Inc., a Waltham, MA-based developer of innovative ophthalmic products based on... | finsmes.co... |
| 12.02.2015 | Will the $350M fund Lux Capital is raising include digital h... | HIPAA compliance Aptible automates HIPAA compliance for Web-based and mobile applications. It manag... | medcitynew... |
| 25.04.2014 | Using nanoparticles, not needles, to deliver drugs into the ... | An aging population is fueling healthy growth in the ophthalmology drug market, led by Pfizer, Aller... | medcitynew... |
Show more